Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	232.92M
Revenue (ttm)	9.56M
Net Income (ttm)	-16.21M
Shares Out	228.36M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,527,058
Open	0.907
Previous Close	0.898
Day's Range	0.907 - 1.030
52-Week Range	0.365 - 1.150
Beta	1.61
Analysts	Strong Buy
Price Target	4.20 (+311.77%)
Earnings Date	Aug 7, 2025

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 77
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: LCTX
• Website: https://www.lineagecell.com

Financial Performance

In 2024, Lineage Cell Therapeutics's revenue was $9.50 million, an increase of 6.19% compared to the previous year's $8.95 million. Losses were -$18.61 million, -13.39% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price target is $4.2, which is an increase of 311.77% from the latest price.

Price Target

$4.2

(311.77% upside)

Analyst Consensus: Strong Buy